MJ biopharma isn’t looking for a lower price. They're looking to get as many shares of Vinergy as they can get. The price they pay for the shares doesn’t matter much because (at the price per share they agreed on) they would recoup their loss as soon as the deal goes through. From Vinergy's perspective, they aren’t trying to get as much money as they can through the deal, they want to acquire MJ biopharma using as few shares as possible. In other words, shares have much more value than money at this point in time. This is why I believe an acquisition that would add immediate and substantial value to Vinergy is in the works. If there wasn’t something else competing for Vinergy's shares, MJ Biopharma would have more leverage in setting the number of shares because they would be soley responisble for Vinergy's value (what Vinergy is looking to increase). In which case, the amendment would have been for more shares, not less.
News 
Market Data 
Discover 
